echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Milestone Pharmaceuticals announces an exclusive license agreement with Jixing Pharmaceuticals

    Milestone Pharmaceuticals announces an exclusive license agreement with Jixing Pharmaceuticals

    • Last Update: 2021-07-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Milestone Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of innovative cardiovascular drugs
    .
    The company today announced that it has reached an exclusive license and cooperation agreement with Jixing Pharmaceutical ("Jixing") to develop in Greater China for patients with paroxysmal supraventricular tachycardia (PSVT) and other cardiovascular diseases The experimental drug Etripamil, and its commercialization will be realized after approval


    .


    "Our vision is to benefit patients with PSVT around the world from Etripamil, and this cooperation marks an important step towards the realization of this vision.
    At the same time, through this cooperation we have also consolidated our financial position and improved our Executive ability
    .
    " said Joseph Oliveto, President and CEO of Milestone Pharmaceuticals


    .


    "Etripamil has the potential to change the treatment model of PSVT


    .


    According to the terms of the agreement, Milestone will grant Jixing the exclusive license to develop and commercialize Etripamil for PSVT patients in Greater China


    .


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.